Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 May 15;15:1399438. doi: 10.3389/fimmu.2024.1399438

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2024 Gordon, Raybould, Wong and Deane

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Humanization is the leading method for generating antibody therapeutics compatible with the human immune system. (A) Genetics of all WHO-recognized antibody- and nanobody-derived therapeutics included in the Thera-SAbDab database (4), by year of proposed International Nonproprietary Name (INN). (B) Developmental origins of therapeutics with a proposed INN before and after 2017 show that humanization is still the predominant means of generating antibodies for therapeutic use. (C) Cumulative number of humanized therapeutics recorded in Thera-SAbDab reaching at least phase-II clinical trials, by year of proposed INN. Statistics for recent therapeutics are likely to increase with time.